Softgels - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe


An industry leader since 1933, Catalent develops and manufactures over 80% of the world's Rx softgel products with 200+ products on the market in 80+ countries supplied by 11 global sites. Catalent is the world leader of softgel drug delivery technologies, the proven solution to deliver more products and better treatments by reliably solving complex bioavailability, solubility, and formulation challenges.

As the originator of the RP Scherer softgel rotary die process, coupled with over 75 years of global manufacturing expertise, Catalent manufactures softgel products across its network of facilities on 5 continents. Catalent demonstrates its softgel expertise in the following therapeutic areas: Omega-3, Vitamin-D analogs, retinoids, antivirals, and hormones. Catalent has unrivalled breadth and depth of expertise in softgel technologies to solve the toughest drug delivery challenges.

Catalent’s new, breakthrough technologies- OptiShell™ for complex fill formulations, OptiGel Bio™ for macromolecules and OptiGel Lock™ for abuse deterrence- can put even more molecules on a faster path to commercialization. Catalent’s broader range of challenging molecules, combined with deep development expertise, advanced delivery technologies and integrated supply solutions enable better outcomes for a broader range of challenging molecules.

Catalent Pharma Solutions

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
FindPharma Custom Search

Click here